Maralixibat Chloride is an oral bile acid transporter inhibitor used in the treatment of pruritus associated with cholestasis in patients with conditions such as Alagille syndrome, progressive familial… Read more
![Chemical structure of (4R,5R)-3,3-Dibutyl-5-(4-((4-(chloromethyl)benzyl)oxy)phenyl)-7-(dimethylamino)-4-hydroxy-2,3,4,5-tetrahydrobenzo[b]thiepine 1,1-dioxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F289038-78-4-4R5R-33-Dibutyl-5-4-4-chloromethylbenzyloxyphenyl-7-dimethylamino-4-hydroxy-2345-tetrahydrobenzobthiepine-11-dioxide.png&w=3840&q=75)
![Chemical structure of (4R,5R)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydrobenzo[b]thiepine 1,1-dioxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F228113-65-3-4R5R-33-Dibutyl-7-dimethylamino-4-hydroxy-5-4-hydroxyphenyl-2345-tetrahydrobenzobthiepine-11-dioxide.png&w=3840&q=75)
![Chemical structure of (4R,5R)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydrobenzo[b]thiepine 1,1-dioxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F228113-64-2-4R5R-33-Dibutyl-7-dimethylamino-4-hydroxy-5-4-methoxyphenyl-2345-tetrahydrobenzobthiepine-11-dioxide.png&w=3840&q=75)
![Chemical structure of (4R,5R)-3,3-Dibutyl-7-fluoro-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydrobenzo[b]thiepine 1,1-dioxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F228113-63-1-4R5R-33-Dibutyl-7-fluoro-4-hydroxy-5-4-methoxyphenyl-2345-tetrahydrobenzobthiepine-11-dioxide.png&w=3840&q=75)
![Chemical structure of 1-(4-((4-((4R,5R)-3,3-Dibutyl-4-hydroxy-7-(methyl(nitroso)amino)-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium Chloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1-4-4-4R5R-33-Dibutyl-4-hydroxy-7-methylnitrosoamino-11-dioxido-2345-tetrahydrobenzobthiepin-5-ylphenoxymethylbenzyl-14-diazabicyclo2.2.2octan-1-ium-C.png&w=3840&q=75)
![Chemical structure of 1-(4-((4-((4R,5R)-3,3-Dibutyl-4-hydroxy-7-(methylamino)-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium Chloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1-4-4-4R5R-33-Dibutyl-4-hydroxy-7-methylamino-11-dioxido-2345-tetrahydrobenzobthiepin-5-ylphenoxymethylbenzyl-14-diazabicyclo2.2.2octan-1-ium-Chloride.png&w=3840&q=75)
![Chemical structure of 1-(4-((4-((4S,5S)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium Chloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F228113-67-5-1-4-4-4S5S-33-Dibutyl-7-dimethylamino-4-hydroxy-11-dioxido-2345-tetrahydrobenzobthiepin-5-ylphenoxymethylbenzyl-14-diazabicyclo2.2.2octan-.png&w=3840&q=75)

Maralixibat Chloride is an oral bile acid transporter inhibitor used in the treatment of pruritus associated with cholestasis in patients with conditions such as Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. As a critical pharmaceutical agent, ensuring its safety and efficacy requires rigorous analytical evaluation throughout the drug development lifecycle. This category provides access to high-quality reference standards for Maralixibat Chloride, including its active pharmaceutical ingredient, related process-related impurities, potential degradation products, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories to perform accurate impurity profiling, facilitate method validation, and maintain stringent quality control standards during manufacturing. By utilizing these chemically characterized substances, researchers can ensure the precision and reliability of their analytical testing protocols for this important therapeutic compound.